MDCXW — Medicus Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1997296 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -8,597,077 | -9,042,143 | 7,426,911 | 6,365,624 | 5,999,017 |
| Dec 2025 | 0 | — | -7,790,600 | -8,184,411 | 10,061,377 | 8,705,218 | 10,024,066 |
| Sep 2025 | 0 | — | -15,426,340 | -15,981,312 | 9,977,661 | 8,662,091 | 10,782,551 |
| Jun 2025 | 0 | — | -6,016,088 | -6,176,084 | 11,934,628 | 9,669,546 | 8,685,918 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,776,769
Investing CF
$0
Financing CF
$31,939,785
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-64,348,118
Inventory
—
Receivables
$14,000
ST Investments
—
EBIT TTM
$-34,359,302
Pretax Income TTM
$-35,444,361
Interest Exp TTM
$805,093
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,359,302 | -35,444,215 | 10,061,377 | 10,024,066 | — | -22,776,769 |
| Dec 2024 | 0 | -11,180,902 | -11,155,516 | 5,646,878 | 2,512,174 | — | -10,247,231 |
| Dec 2023 | 0 | -2,658,365 | -5,314,765 | 1,893,057 | 781,609 | — | -4,158,264 |
| Dec 2022 | 0 | -978,416 | -1,692,382 | 282,652 | 12,480,684 | — | -1,057,103 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $949.47B | $1064.74 | — |
| JNJ | JOHNSON & JOHNSON | $554.09B | $230.18 | — |
| ABBV | AbbVie Inc. | $376.54B | $213.12 | — |
| MRK | Merck & Co., Inc. | $295.69B | $119.72 | — |
| AZN | ASTRAZENECA PLC | $290.30B | $187.19 | — |
News headlines (Yahoo Finance, 1h cache)
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
2026-05-19 11:10 · Yahoo
Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress
2026-05-15 12:28 · Yahoo
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 20:30 · Yahoo
EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study
2026-05-07 23:31 · Yahoo
Medicus Pharma reports strong Phase 2 dose response in skin cancer study
2026-05-06 16:12 · Yahoo
Medicus Pharma highlights positive dose-response in updated skin cancer trial results
2026-05-06 13:27 · Yahoo
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
2026-05-06 11:30 · Yahoo
Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome
2026-04-27 13:23 · Yahoo
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
2026-04-27 11:30 · Yahoo
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
2026-04-25 16:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.